regeneron Archives - Vista Partners LLC

Eupraxia, Dupixent, and the Race to Redefine EoE Care -( $EPRX $REGN $SNY )

by John F. Heerdink, Jr. May 18, 2026 285Views 0Likes

Eupraxia’s (NASDAQ: EPRX) current analyst chorus post their most recent First Quarter 2026 Financial Results report is now singing from the same hymn book: this is a late-stage GI platform story with cash in the bank, near-term catalysts, and price targets that…

From Antibodies to Atoms: Inside the Telix–Regeneron Tie-Up and NAYA’s Radiopharma Supply-Chain Fortress -( $REGN $IBB $XBI )

by John F. Heerdink, Jr. April 15, 2026 318Views 0Likes

Telix, Regeneron (REGN), and NAYA Therapeutics are turning radiopharmaceuticals into one of Wall Street’s more serious new growth stories—while quietly building the kind of supply-chain moats that would make an oil baron blush. Telix and Regeneron: A $2 Billion Bet on “Hot”…

Eupraxia Steps Into the Spotlight: AAAAI 2026 Puts EoE Back on the Growth Map -( $EPRX $SNY $REGN $IBB $XBI )

by John F. Heerdink, Jr. March 2, 2026 469Views 0Likes

In a conference season dominated by mega-cap immunology franchises, Eupraxia Pharmaceuticals (NASDAQ: EPRX) quietly walked into AAAAI 2026 and walked out looking a lot less “micro‑cap” and a lot more “mispriced asset.” For investors willing to do more than skim the abstracts,…

Tag: regeneron

Eupraxia, Dupixent, and the Race to Redefine EoE Care -( $EPRX $REGN $SNY )

From Antibodies to Atoms: Inside the Telix–Regeneron Tie-Up and NAYA’s Radiopharma Supply-Chain Fortress -( $REGN $IBB $XBI )

Eupraxia Steps Into the Spotlight: AAAAI 2026 Puts EoE Back on the Growth Map -( $EPRX $SNY $REGN $IBB $XBI )

Your Guide To Staying Informed In The Markets